Therapeutics News and Research

RSS

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

MedPharm receives new patents for MedSpray topical spray-on-film technology

MedPharm Ltd, the topical drug development specialist, today announced it has been granted a series of further patents for its novel MedSpray topical spray-on-film technology for dermatological, topical and transdermal drug delivery.

6 Aug 2013

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

...

6 Aug 2013

Bayer Collaboration Could Net $540M+ For Compugen

...

6 Aug 2013

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Compugen Ltd. announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators.

5 Aug 2013

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division

Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.

2 Aug 2013

Thermo Fisher Scientific opens cell culture DPM production site in Singapore

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it is expanding its global cell culture and bioprocessing capabilities by opening a new manufacturing plant in Singapore to produce dry powder media, a crucial cell culture raw material used to manufacture biologics, including vaccines, anti-cancer therapeutics, and others.

2 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Cancer biomarker tests undervalued by doctors and patients, authors say

There's a major roadblock to creating personalized cancer care. Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.

2 Aug 2013

Microbiologists identify staph-killing compound that may be effective for osteomyelitis

Osteomyelitis, a debilitating bone infection most frequently caused by Staphylococcus aureus ("staph") bacteria, is particularly challenging to treat.

2 Aug 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

Research opens potential new avenue for cancer treatment

Scientists at The University of Texas MD Anderson who identified a protein's dual role in cancer promotion have discovered a way to shut it down, opening a potential new avenue for cancer treatment.

2 Aug 2013

Viropharma announces financial results for second quarter of 2013

VIROPHARMA INCORPORATED (Nasdaq: VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012.

1 Aug 2013

Intrinsic Therapeutics enrolls 400th patient in randomized clinical trial to evaluate effectiveness of Barricaid prosthesis

Intrinsic Therapeutics today announced the enrollment of the 400th patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica.

1 Aug 2013

Researchers identify novel approach to enhance tissue repair and organ regeneration

Because most human tissues do not regenerate spontaneously, advances in tissue repair and organ regeneration could benefit many patients with a wide variety of medical conditions.

1 Aug 2013

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

The National Institutes of Health has launched three innovative projects that will focus on development of therapeutics for Fragile X syndrome, nicotine addiction, and age-related macular degeneration. These projects are funded through the NIH Blueprint Neurotherapeutics Network which provides access to a variety of drug development resources.

1 Aug 2013

Novel protein could lead to development of new drugs to treat variety of cancers

In cancer research, discovering a new protein that plays a role in cancer is like finding a key and a treasure map: follow the clues and eventually there could be a big reward. At least that's the hope from a new study published in the journal Nature that discovered a novel protein called ceramide-1 phosphate transport protein (CPTP) -- a finding that could eventually lead to the development of new drugs to treat a variety of cancers and other conditions involving inflammation and thrombosis, or blood clotting.

1 Aug 2013

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.

31 Jul 2013

Naurex receives new U.S. patent for its lead compound, GLYX-13

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13.

31 Jul 2013

CHOP researchers advance stem cell studies in childhood leukemia, Diamond Blackfan anemia

First produced only in the past decade, human induced pluripotent stem cells are capable of developing into many or even all human cell types. In new research, scientists reprogrammed skin cells from patients with rare blood disorders into iPSCs, highlighting the great promise of these cells in advancing understanding of those challenging diseases-and eventually in treating them.

31 Jul 2013

Therapeutics News and Research

Ensemble Therapeutics initiates research and development collaboration with Novartis

MedPharm receives new patents for MedSpray topical spray-on-film technology

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

Bayer Collaboration Could Net $540M+ For Compugen

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division

Thermo Fisher Scientific opens cell culture DPM production site in Singapore

ImmunoGen reports net loss of $21.9 million in Q4 2013

Cancer biomarker tests undervalued by doctors and patients, authors say

Microbiologists identify staph-killing compound that may be effective for osteomyelitis

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

Research opens potential new avenue for cancer treatment

Viropharma announces financial results for second quarter of 2013

Intrinsic Therapeutics enrolls 400th patient in randomized clinical trial to evaluate effectiveness of Barricaid prosthesis

Researchers identify novel approach to enhance tissue repair and organ regeneration

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

Novel protein could lead to development of new drugs to treat variety of cancers

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Naurex receives new U.S. patent for its lead compound, GLYX-13

CHOP researchers advance stem cell studies in childhood leukemia, Diamond Blackfan anemia

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News